Ginkgo Bioworks secured a project agreement through BARDA’s BioMaP Consortium valued up to $22.2 million to develop cost‑reducing, scalable monoclonal antibody manufacturing for filovirus countermeasures. Ginkgo will lead a consortium including Emory University, Advanced BioScience Laboratories, Isolere Bio, NeuImmune and ProteoNic BV to produce and integrate innovations across discovery, expression, and bioprocessing focused on an anti‑filovirus mAb cocktail from Emory. The work aims to improve domestic surge capacity for medical countermeasures and reduce costs for mAb production.